SYDNEY, June 21, 2022 (GLOBE NEWSWIRE) -- Parnell Pharmaceuticals Holdings Ltd (OTC: PARNF), a fully integrated, commercial-stage pharmaceutical company focused on developing, manufacturing and...
SAN RAFAEL, Calif., Sept. 23, 2020 /PRNewswire/ -- Parnell Pharmaceuticals announced that it has developed what will be the first antiviral nasal spray in the United States. Nomovid™ Nasal Spray will be easy-to-use, low-cost and can be quickly made available over-the-counter for consumers.
Parnell Pharmaceuticals Holdings Ltd (NASDAQ:PARN), a fully integrated, commercial-stage pharmaceutical company focused on developing, manufacturing and marketing innovative animal health solutions (“Parnell” or the “Company”), today announced that it will file a Form 25, Notification of Removal from Listing and/or Registration under Section 12(b) of the Securities Exchange Act, with the Securities and Exchange Commission and NASDAQ on December 21, 2016.